FDA’s Drug Detention Reg Follows Devices Oversight Model
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposed rule implementing new FDASIA authority to administratively detain drugs believed to be adulterated or misbranded largely mirrors regulations already in place for medical devices, the agency said.